Contrasting Aspyra (OTCMKTS:APYI) and Predictive Oncology (NASDAQ:POAI)

Predictive Oncology (NASDAQ:POAI) and Aspyra (OTCMKTS:APYI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Earnings & Valuation

This table compares Predictive Oncology and Aspyra”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.62 million	11.45	-$12.66 million	($13.50)	-0.41
Aspyra	N/A	N/A	N/A	N/A	N/A

Aspyra has lower revenue, but higher earnings than Predictive Oncology.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Predictive Oncology and Aspyra, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1	0	0	0	1.00
Aspyra	0	0	0	0	0.00

Insider and Institutional Ownership

9.0% of Predictive Oncology shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 23.9% of Aspyra shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Predictive Oncology and Aspyra’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Aspyra	N/A	N/A	N/A

Volatility & Risk

Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Aspyra has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Summary

Aspyra beats Predictive Oncology on 5 of the 8 factors compared between the two stocks.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

About Aspyra

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.